argenx SE

ARGX • Biotechnology

$1033.15

▼ -20.31 (-1.93%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$52.81B

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Márgenes estables o en mejora · 31.1%Crecimiento positivo de ingresos · 62.4%Flujo de caja libre positivo · 13.77Nivel de deuda manejable · 0.01Liquidez saludable · 5.23

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 31 dic 2025, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1,033.15

Change-1.93%

Market Cap$52.81B

52W Range510.06 - 934.62

Beta-0.03

Gross Margin89.15%

Oper. Margin25.39%

Profit Margin31.11%

Debt/Eq0.01

Current Ratio5.23

Quick Ratio4.87

Target$1,136.83

Price$1,033.15

Change-1.93%

Market Cap$52.81B

52W Range510.06 - 934.62

Beta-0.03

Gross Margin89.15%

Oper. Margin25.39%

Profit Margin31.11%

Debt/Eq0.01

Current Ratio5.23

Quick Ratio4.87

Target$1,136.83

Target Upside10.04%

Target Median$1,152.50

Target Range940.00 - 1291.00

Volume714.48K

Avg Volume327.48K

EPS Surprise-0.37

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

25/100

Por qué este puntaje▼

Márgenes estables o en mejora · 31.1%Crecimiento positivo de ingresos · 62.4%Flujo de caja libre positivo · 13.77Nivel de deuda manejable · 0.01Liquidez saludable · 5.23Múltiplo de ganancias caro · 39.9

Analyst view

Analyst sentiment and price target

Analyst sentiment

No vote count available

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$940.00

Promedio

$1136.83

Mediana

$1152.50

Alto

$1291.00

Resumen de la compañía

IPO: 5/18/2017

Industria: Biotechnology

P/B i: 7.04

Deuda / Patrimonio i: 0.01

Margen operativo: 25.39%

Margen neto: 31.11%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 5.23

Ratio rápido: 4.87

Estado: Strong

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

argenx SE

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

Fuente - Link

Competidores

A ALC ALNY BDX CAH EW HLN IDXX REGN VEEV

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

📰

No hay noticias disponibles ahora

Vuelve a revisar más tarde.

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	6.27	5.9	-0.37
2025-10-30	4.37	5.18	0.81
2025-05-08	0.98	2.58	1.6
2024-10-31	0.1	1.39	1.29
2024-05-09	-0.71	-1.04	-0.33
2023-10-31	-1.48	-1.25	0.23
2023-05-04	-2.34	-0.52	1.82
2022-10-27	-3.5	-4.26	-0.76
2021-10-28	-4.48	-4.4	0.08
2021-05-14	-3.14	-0.81	2.33
2020-10-22	-2.39	-3.39	-1
2020-05-14	-1.88	-2.06	-0.18